I’ve been deeply immersed in Long COVID research for years now. Today, I want to share my thoughts on a heartbreaking case that highlights the urgent need for clarity in how we define and approach this condition. It’s the story of Eva Rodrigues Praia Walkey, a talented Brazilian singer who recently passed away at the age of 40 after a grueling five-year battle with what has been labeled as Long COVID.
Overview of Case
Eva’s ordeal began in early 2021, during the height of the COVID-19 pandemic’s second wave in Brazil. At 38 weeks pregnant with her third child, she was admitted to the hospital with severe COVID-19 symptoms, including acute respiratory distress and dangerously low oxygen levels.
Her condition worsened rapidly, leading to an emergency cesarean section to deliver her son, Ethan. Tragically, due to her critical state, she couldn’t hold or bond with her newborn immediately. Shortly after the delivery, Eva was intubated and placed on mechanical ventilation for 16 days to support her failing lungs. She underwent a tracheostomy for long-term airway management and suffered two cardiac arrests during her hospital stay.
The infection caused extensive lung damage, necessitating the surgical removal of about 20% of her lung tissue. Additionally, she faced neurological complications, including seizures and convulsions, along with secondary hospital-acquired infections that persisted for months and required aggressive antibiotic treatments, even importing medications from abroad.
Her hospitalization stretched over an astonishing 400 days, much of it spent in intensive care. Even after discharge, Eva dealt with lasting pulmonary fibrosis, neurological sequelae, and ongoing symptoms that severely impacted her quality of life. Despite moments of hope and family support, her body never fully recovered from the initial severe assault of the virus, ultimately leading to her death five years later from complications attributed to Long COVID.
This case is profoundly sad, not just for Eva and her family, but for what it reveals about the broader challenges in Long COVID research and treatment. I’ve been following stories like hers for a long time, and one of the biggest issues I see is the overly broad definitions we use for Long COVID.
Danger of Weak Science
By lumping together cases like Eva’s—marked by severe, acute COVID-19 with irreversible organ damage—with what I call “pure” Long COVID, where individuals experience chronic autoimmune and inflammatory symptoms after a mild infection, we’re muddying the waters. These are two distinct scenarios with different pathophysiology.
In Eva’s situation, her symptoms stemmed from the direct, devastating effects of severe COVID-19: lung fibrosis from prolonged ventilation and infection, cardiac events, and neurological damage from hypoxia and inflammation during the acute phase. It’s essentially COVID complications persisting long-term.
This isn’t the same as someone who had a mild case but later develops unexplained breathlessness, fatigue, or brain fog without visible structural damage on scans. Don’t get me wrong—people who’ve had severe COVID can absolutely develop overlapping Long COVID symptoms, creating a more complex picture with multiple pathophysiology at play. But without clear differentiation, we risk going in circles with research and treatment.
For instance, if someone has significant fibrotic changes in their lungs from severe COVID, like Eva did, there’s limited scope for reversal; management focuses on symptom mitigation and supportive care. On the other hand, for those with no obvious pathology but persistent symptoms driven by ongoing inflammation or autoimmunity, identifying the root cause could open doors to targeted therapies that genuinely improve outcomes.
Final Thoughts
This lack of precision damages the narrative around Long COVID. It confuses patients, frustrates clinicians, and hinders progress in developing effective treatments. We need to be more accurate in understanding and categorizing pathophysiology to avoid diluting efforts and to prioritize cases where interventions can make the most difference.
At the end of the day, my heart goes out to Eva, her family, and the countless others whose lives have been upended by Long COVID in all its forms. Stories like hers remind us of the human cost and the imperative to push forward with rigorous, differentiated research. If we can refine our approach, we stand a better chance of helping those still fighting this battle.
Thank you for reading—let’s keep the conversation going.
